Hormonal therapy and thromboembolic disease

Bartłomiej Barczyński; Jan Kotarski

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2008
vol. 7

Send email

Copy url:

abstract:

Hormonal therapy and thromboembolic disease

Bartłomiej Barczyński

,

Jan Kotarski

Przegląd Menopauzalny 2008; 3: 127–131

Online publish date: 2008/07/07

View full text Get citation

One of the most serious adverse effects of oral contraceptive therapy and hormonal therapy (HT) is thromboembolic disease. According to the literature use of oral oestrogen-based HT causes a 2-3-fold increased relative risk for thromboembolic events in perimenopausal women. The risk of thromboembolic complications is dependent on the type of oestrogen and progestogen. The number of unfavourable adverse events may be effectively reduced by changing the route of HT administration (from oral to transdermal), decreasing the dose of oestrogen component and/or changing the type of progestogen component. Implementation of hormonal treatment should in all cases be individualized and based on the patient’s needs and expectations as well as general health status.

keywords:

Hormonal therapy and thromboembolic disease

Bartłomiej Barczyński , Jan Kotarski

hormonal therapy, thromboembolic disease

Bartłomiej Barczyński

,

Jan Kotarski